HOLISTA COLLTECH LIMITED — Interim / Quarterly Report 2018

Oct 29, 2018

Holista CollTech Limited (ASX:HCT / ABN 24 094 515 992) 283 Rokeby Road Subiaco WA 6008 P: +61 8 6141 3500 ; F: +61 8 6141 3599 W: www.holistaco.com

ASX Announcement

30 October 2018

HOLISTA COLLTECH LIMITED APPENDIX 4C

Holista CollTech Limited (“Holista”, or the “Company”) (ASX CODE: HCT) is pleased to release the Appendix 4C for the quarter ending 30 September 2018.

On 26[th] June 2018, Holista announced a Share Purchase Plan(“SPP”). Shareholders have been extremely supportive with their participation in the SPP and the placement linked to the SPP was fully subscribed. Dr Rajen Manicka and Chan Heng Fai converted what the company owed them to equity. Holista placed 40 million shares at 7 cents worth $2.8 million as we closed on 25[th] July.

We are thankful to all our shareholders who have been extremely supportive. We also pleased to welcome so many new shareholders.

“We are pleased to again show a positive cash position this quarter”, says Dr Rajen Manicka, Managing Director. “This result is on the back of improved operations in Holista’s various businesses across the world. The Company has enjoyed significant progress in the production and distribution of Holista’s Low GI and Gluten free range of food ingredients into north America and the supplements business continues to grow in its markets. The Company still anticipates growth in the noodle market toward the final quarter of 2018 after overcoming some regulatory challenges in China.”

“The Company has worked through some technical matters regarding the production of collagen that are now resolved. In the final quarter of 2018, all orders in Asian region for cosmetic collagen will be fulfilled. The Company is now positioned for new growth in these markets.” commented Dr Rajen.

During the next quarter the Company plans to continue its investment into food grade collagen and to finally complete its plans to develop nano sized collagen for food and cosmetic applications.

For further information, please contact:

Corporate Affairs & Business Opportunities

Dr Rajen Manicka: rajen.m@holistaco.com General Enquiries: enquiries@holistaco.com

Australia

283 Rokeby Road Subiaco WA 6008 P: +61 8 6141 3500 ; F: +61 8 6141 3599

Malaysia

12th Floor, Amcorp Trade Centre, PJ Tower No. 18, Persiaran Barat off Jalan Timur 46000, Petaling Jaya, Malaysia P: +603 7965 2828 ; F: +603 7965 2777

Media and Investor Relations Enquiries

WeR1 Consultants Pte Ltd 3 Phillip Street #12-01 Singapore 048693 May Barza, maybarza@wer1.net; P: +65 67374844

About Holista CollTech Ltd

Holista CollTech Ltd ( Holista ) is a research-driven biotech company and is the result of the merger of Holista Biotech Sdn Bhd and CollTech Australia Ltd. Headquartered in Perth with extensive operations in Malaysia, Holista is dedicated to delivering first-class natural ingredients and wellness products and leads in research on herbs and food ingredients.

Holista, listed on the Australia Securities Exchange, researches, develops, manufactures and markets “healthstyle” products to address the unmet and growing needs of natural medicine. Holista’s suite of ingredients is capable of serving the industry to provide low-GI baked products, low sodium salt, low fat fried foods and low calories sugar without compromise in taste, odour and mouth feel. It is the only company to produce sheep (ovine) collagen using patented extraction methods.

Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B

Rule 4.7B

Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

HOLISTA COLLTECH LIMITED (ASX:HCT)

==> picture [442 x 504] intentionally omitted <==

----- Start of picture text -----

ABN Quarter ended ( Current quarter )
24 094 515 992 30 September 2018
Current Year to date
Consolidated statement of cash flows quarter (9 Months)
$A'000 $A'000
1. Cash flows from operating activities
1.1 Receipts from customers [‡] 1,998 5,690
1.2 Payments for: - -
(a) research and development (45) (123)
(b) product manufacturing and operating costs [ǂ] (1,606) (2,898)
(c) advertising and marketing (256) (469)
(d) leased assets - -
(e) staff costs (787) (2,322)
(f) administration and corporate costs (766) (1,398)
1.3 Dividends received (see note 3) - -
1.4 Interest received - -
1.5 Interest and other costs of finance paid (18) (62)
1.6 Income taxes (paid) / refunded (19) (40)
1.7 Government grants and tax incentives - -
1.8 Other (provide details if material)
1.9 Net cash from / (used in) operating activities (1,499) (1,622)
2. Cash flows from investing activities
2.1 Payments to acquire:
(a) property, plant and equipment [ǂ] (15) (65)
(b) businesses (see item 10) - -
(c) investments - -
(d) intellectual property [ǂ] - (104)
(e) other non-current assets - -
2.2 Proceeds from disposal of:
(a) property, plant and equipment - -
(b) businesses (see item 10) - -
(c) investments - -
(d) intellectual property - -
(e) other non-current assets [ǂ] (4) 227
2.3 Cash flows from loans to other entities (288) (288)
2.4 Dividends received (see note 3) - -
2.5 Other (provide details if material): - -
2.6 Net cash from / (used in) investing activities (307) (230)
----- End of picture text -----

• Year to date balances have been adjusted to match the auditor reviewed 2018 June Interim Financial Statements

• See chapter 19 for defined terms 1 September 2016

Page 1

Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B

==> picture [443 x 509] intentionally omitted <==

----- Start of picture text -----

Current Year to date
Consolidated statement of cash flows quarter (9 Months)
$A'000 $A'000
3. Cash flows from financing activities
3.1 Proceeds from issues of shares 2,362 2,362
3.2 Proceeds from issue of convertible notes 210 210
3.3 Proceeds from exercise of share options - -
3.4 Transaction costs related to issues of shares, convertible notes or options - -
3.5 Proceeds from borrowings - 75
3.6 Repayment of borrowings (7) (7)
3.7 Transaction costs related to loans and borrowings - -
3.8 Dividends paid - -
3.9 Other (provide details if material) - -
3.10 Net cash from / (used in) financing activities 2,565 2,640
4. Net increase / (decrease) in cash and cash equivalents for the period
4.1 Cash and cash equivalents at beginning of quarter/year to date 158 121
4.2 Net cash from / (used in) operating activities (item 1.9 above) (1,499) (1,622)
4.3 Net cash from / (used in) investing activities (item 2.6 above) (307) (230)
4.4 Net cash from / (used in) financing activities (item 3.10 above) 2,565 2,640
4.5 Effect of movement in exchange rates on cash held - 8
4.6 Cash and cash equivalents at end of quarter 917 917
5. Reconciliation of cash and cash equivalents Current Previous
at the end of the quarter (as shown in the consolidated statement of quarter quarter
cash flows) to the related items in the accounts $A'000 $A'000
5.1 Bank balances 311 158
5.2 Call deposits 606 -
5.3 Bank overdrafts - -
5.4 Other (provide details) - -
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above) 917 158
6. Payments to directors of the entity and their associates Current
quarter
$A'000
6.1 Aggregate amount of payments to these parties included in item 1.2 89
6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3 and 2.5 -
6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2
In respect to 6.1: Salaries and consulting fees paid to directors and their related parties.
----- End of picture text -----

6.1 Aggregate amount of payments to these parties included in item 1.2 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3 and 2.5 6.3 Include below anyexplanation necessaryto understand the transactions included in items In respect to 6.1: Salaries and consulting fees paid to directors and their related parties.	$A'000 89 - 6.1 and 6.2
7. Payments to related entities of the entity and their associates 7.1 Aggregate amount of payments to these parties included in item 1.2 7.2 Aggregate amount of cash flow from loans to these parties included in items 2.3 7.3 Include below anyexplanation necessaryto understand the transactions included in items	Current quarter $A'000
	-
	-
	7.1 and 7.2
Nil

Nil

• See chapter 19 for defined terms 1 September 2016

Page 2

Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B

8.	Financing facilities available Add notes as necessary for an understanding of the position	Total facility amount at quarter end $A'000	Amount drawn at quarter end $A'000
8.1	Loan facilities	501	501
8.2	Credit standby arrangements	268	259
8.3	Other (please specify)	-	-
8.4	Include below a description of each facility above, including the lender, interest rate and whether it is
	secured or unsecured. If any additional facilities have been entered into or are proposed to be entered
	into afterquarter end, include details of those facilities as well.

Loan facilities-This is secured term loan with RHB bank in Malaysia, interest rates ranging from 4.76% to 6.73%. Credit standby arrangements-This is banker acceptance bears interest of 5.15% with CIMB bank in Malaysia. This is secured loan by pledging fixed deposits.

==> picture [442 x 122] intentionally omitted <==

----- Start of picture text -----

9. Estimated cash outflows for next quarter $A'000
9.1 Research and development 72
9.2 Product manufacturing and operating costs 1,026
9.3 Advertising and marketing 178
9.4 Leased assets -
9.5 Staff costs 759
9.6 Administration and corporate costs 328
9.7 Other (provide details if material): -
9.8 Total estimated cash outflows 2,363
----- End of picture text -----

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above) 10.1 Name of entity 10.2 Place of incorporation or registration 10.3 Consideration for acquisition or disposal 10.4 Total net assets / (deficiency) 10.5 Nature of business	Acquisitions	Disposals
	-	-
	-	-
	-	-
	-	-
	-	-

Compliance statement

1. This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2. This statement gives a true and fair view of the matters disclosed.

Signed: Dated: Tuesday, 30 October 2018

Company Secretary

Print name: BRETT FRASER

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.

2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. See chapter 19 for defined terms 1 September 2016

Page 3